Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
n this study, approximately 30 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) were recruited for a single reinfusion of IM19-CD28 and IM19-41BB CAR-T cells. Assess the safety, tolerability of treatment, and initially observe the efficacy.
Non Hodgkin Lymphoma
BIOLOGICAL: IM19|DRUG: Fludarabine|DRUG: Cyclophosphamide
Occurrence of study related adverse events, \>= Grade 3 signs/symptoms,laboratory toxicities,and clinical events that are possibly,likely,or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2., 2 years
Overall response rate, (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014), 2 years
1. Dose-escalation:Patients entered the IM19-41BB or IM19-CD28 group and performed dose escalation studies in three dose groups.
2. According to the results of the previous dose escalation study, select one dose to continue the enrollment of 6 patients for extended studies.